Microbiotica has received the green light from EU and UK regulatory authorities to start phase 1b studies for its microbiome medicines in advanced melanoma and ulcerative colitis.
Health Professionals
Nivolumab Combinations Debated for a Patient With Metastatic Melanoma
During a Case-Based Roundtable® event, Hussein A. Tawbi, MD, PhD, and participants considered nivolumab/ipilimumab and nivolumab/relatlimab as options for a patient with metastatic melanoma in the first article of a 2-part series.
Dual Checkpoint Blockade Usurps PD-1 Monotherapy as Gold Standard in Unresectable Melanoma
Updated findings from the phase 2/3 RELATIVITY-047 trial (NCT03470922) showing sustained responses and favorable survival outcomes with nivolumab (Opdivo) plus relatlimab-rmbw (Opdualag) in previously untreated patients with metastatic or unresectable melanoma signal the diminishing role for anti–PD-1 monotherapy in the frontline setting, according to Ankit Mangla, MD.
RELATIVITY-048 Data Highlight Potential of Triplet ICI Regimen for Advanced Melanoma
The addition of ipilimumab (Yervoy) to nivolumab and relatlimab-rmbw (Opdualag) has generated high response rates and promising survival outcomes as a first-line treatment for patients with advanced melanoma in the phase 1/2 RELATIVITY-048 trial (NCT03459222), signifying the viability of triplet checkpoint blockade for this patient population, according to Ankit Mangla, MD. However, larger studies are needed to confirm the efficacy and safety of this approach for use in the frontline setting.